Hydroxychloroquine use and decreased risk of diabetes in rheumatoid arthritis patients

Journal of Clinical Rheumatology

Volumn 17, Issue 3, 2011, Pages 115-120

  Bili, Androniki ^a   Sartorius, Jennifer A ^b   Kirchner, H Lester ^b   Morris, Stephanie J ^a   Ledwich, Lindsay J ^a,c   Antohe, Jana L ^a   Dancea, Sorina ^a   Newman, Eric D ^a   Wasko, Mary Chester M ^c  

^a GEISINGER HEALTH SYSTEM   (United States)

^b Geisinger Center for Health Research   (United States)

^c ALLEGHENY HEALTH NETWORK   (United States)

Author keywords

diabetes mellitus; hydroxychloroquine; rheumatoid arthritis

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; GLUCOCORTICOID; HYDROXYCHLOROQUINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ARTICLE; BODY MASS; DIABETES MELLITUS; ELECTRONIC MEDICAL RECORD; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HAZARD RATIO; HEALTH CARE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; TREATMENT OUTCOME;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYCHLOROQUINE; INCIDENCE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 79955061482     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/RHU.0b013e318214b6b5     Document Type: Article

References (35)

1. Wasko MC. Rheumatoid arthritis and cardiovascular disease. Curr Rheumatol Rep. 2008;10:390-397.
2. Wasko MC, Hubert HB, Lingala VB, et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA. 2007;298:187-193. (Pubitemid 47057765)
3. Solomon DH, Mogun H, Schneeweiss S. Hydroxychloroquine is associated with a reduced risk of diabetes among older adults with rheumatoid arthritis. Arthritis Rheum. 2008;58:S268.
4. Rekedal LR, Massarotti E, Garg RK, et al. The effect of hydroxychloroquine and methotrexate on glycated hemoglobin. Arthritis Rheum. 2009;60(suppl 10):58.
5. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-324. (Pubitemid 18091653)
6. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes care. 2010;33:S62.
7. Giles JT, Bartlett SJ, Andersen RE, et al. Association of body composition with disability in rheumatoid arthritis: impact of appendicular fat and lean tissue mass. Arthritis Rheum. 2008;59:1407-1415.
8. Dessein PH, Stanwix AE, Joffe BI. Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res. 2002;4:R5.
9. Solomon DH, Karlson EW, Rimm EB, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis [see comment]. Circulation. 2003;107:1303-1307. (Pubitemid 36314415)
10. Doran MF, Pond GR, Crowson CS, et al. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period [see comment]. Arthritis Rheum. 2002;46:625-631. (Pubitemid 34214244)
11. Alkaabi JK, Ho M, Levison R, et al. Rheumatoid arthritis and macrovascular disease. Rheumatology (Oxford). 2003;42:292-297. (Pubitemid 36312933)
12. del Rincon ID, Williams K, Stern MP, et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2001;44:2737-2745. (Pubitemid 34016192)
13. Simard JF, Mittleman MA. Prevalent rheumatoid arthritis and diabetes among NHANES III participants aged 60 and older. J Rheumatol. 2007;34:469-473. (Pubitemid 46363999)
14. Solomon DH, Love TJ, Canning C. Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis [published online ahead of print June 28, 2010]. Ann Rheum Dis. Doi: 10.1136/ard.2009.125476
15. Haffner SM. Pre-diabetes, insulin resistance, inflammation and CVD risk. Diabetes Res Clin Pract. 2003;61:S9-S18. (Pubitemid 36918317)
16. Kiortsis DN, Mavridis AK, Filippatos TD, et al. Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol. 2006;33:921-923.
17. Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C, et al. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2006;24:83-86.
18. Tayek JA, Katz J. Glucose production, recycling, Cori cycle, and gluconeogenesis in humans: relationship to serum cortisol. Am J Physiol. 1997;272:E476-E484.
19. Da Silva JA, Jacobs JW, Kirwan JR, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis. 2006;65:285-293. (Pubitemid 43268214)
20. Pisu M, James N, Sampsel S, et al. The cost of glucocorticoid-associated adverse events in rheumatoid arthritis. Rheumatology (Oxford). 2005;44:781-788. (Pubitemid 41487210)
21. van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, et al. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med. 2002;136:1-12. (Pubitemid 34038692)
22. Kirwan JR. Systemic low-dose glucocorticoid treatment in rheumatoid arthritis. Rheum Dis Clin North Am. 2001;27:389-403. (Pubitemid 32488712)
23. La Montagna G, Cacciapuoti F, Buono R, et al. Insulin resistance is an independent risk factor for atherosclerosis in rheumatoid arthritis. Diab Vasc Dis Res. 2007;4:130-135. (Pubitemid 47167497)
24. Fleischman A, Shoelson SE, Bernier R, et al. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care. 2008;31:289-294. (Pubitemid 351213338)
25. Huvers FC, Popa C, Netea MG, et al. Improved insulin sensitivity by anti-TNFalpha antibody treatment in patients with rheumatic diseases. Ann Rheum Dis. 2007;66:558-559. (Pubitemid 46580485)
26. Goldman FD, Gilman AL, Hollenback C, et al. Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties. Blood. 2000;95:3460-3466. (Pubitemid 30428477)
27. Kalia S, Dutz JP. New concepts in antimalarial use and mode of action in dermatology. Dermatol Ther. 2007;20:160-174. (Pubitemid 350029307)
28. Kyburz D, Brentano F, Gay S. Mode of action of hydroxychloroquine in RA-evidence of an inhibitory effect on toll-like receptor signaling. Nat Clin Pract Rheumatol. 2006;2:458-459. (Pubitemid 44340417)
29. Lafyatis R, York M, Marshak-Rothstein A. Antimalarial agents: closing the gate on Toll-like receptors?. Arthritis Rheum. 2006;54:3068-3070. (Pubitemid 44622073)
30. Quatraro A, Consoli G, Magno M, et al. Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus. A new job for an old drug? Ann Intern Med. 1990;112:678-681. (Pubitemid 20137177)
31. Gerstein HC, Thorpe KE, Taylor DW, et al. The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas - a randomized trial. Diabetes Res Clin Pract. 2002;55:209-219. (Pubitemid 34163292)
32. Penn SK, Kao AH, Schott LL, et al. Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol. 2010;37:1136-1142.
33. Ünübol M, Ayhan M, Guney E. Hypoglycemia induced by hydroxychloroquine in a patient treated for rheumatoid arthritis. J Clin Rheumatol. 2011;17:46-47.
34. Shojania K, Koehler BE, Elliott T. Hypoglycemia induced by hydroxychloroquine in a type II diabetic treated for polyarthritis. J Rheumatol. 1999;26:195-196. (Pubitemid 29051417)
35. Cansu DU, Korkmaz C. Hypoglycaemia induced by hydroxychloroquine in a non-diabetic patient treated for RA. Rheumatology (Oxford). 2008;47:378-379. (Pubitemid 351267213)